Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 15

Results For "Synthesis"

144 News Found

Govt. receives 215 applications for the 36 products under PLI scheme
News | March 13, 2021

Govt. receives 215 applications for the 36 products under PLI scheme

174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.

Aarti Speciality Chemicals receives PLI approval for pharmaceutical sector
News | March 08, 2021

Aarti Speciality Chemicals receives PLI approval for pharmaceutical sector

The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.

DSM secures victory in patent infringement litigation against Anhui Tiger
News | March 02, 2021

DSM secures victory in patent infringement litigation against Anhui Tiger

Tiger can no longer make an important biotin intermediate using a DSM patented process.

Laurus Q3 FY21 revenue up 76%; PAT grows 274%
News | January 29, 2021

Laurus Q3 FY21 revenue up 76%; PAT grows 274%

The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.

Latest Stories

Caplin Point Laboratories’ injectables facility completes INVIMA audit successfully

Indoco receives EIR from the USFDA for its API manufacturing facility at Patalganga

Eiko LifeSciences to acquire 51% stake in SSM Formulations

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging